https://www.selleckchem.com/pr....oducts/nazartinib-eg
sm was not associated with changes in REE. High baseline BMI, but not weight loss during therapy, was associated with improvement in QoL. This trail is registered with www.Clinicaltrials.gov (registration no. https//clinicaltrials.gov/ct2/show/NCT02891668).The safety of teriparatide has been studied in various phase III and phase IV trials. However, a postmarketing study of the biosimilar of teriparatide, CinnoPar®, has not been conducted on Iranian patients. This was a phase IV study conducted on osteoporotic patients
Kao
Komentar
Udio
